Q2 FY2026 EarningsQ2 FY2026 results showed a significant revenue beat of $0.28M vs. $0.02M expected, driven by the early FDA approval and immediate U.S. launch of Lumvoa. However, GAAP EPS of -$1.05 missed the -$1.04 consensus due to a surge in SG&A expenses ($55.0M) related to commercial infrastructure build-out. With a strong cash position of $981.5M and elegrobart on track for BLA submission in Q1 2027, the company transitioned to a commercial-stage entity with higher-than-expected operating losses.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Viridian Therapeutics(VRDN) the Revenue is 284 K (+278.7%), Beat estimate;the EBIT is -126.27 M (-18.27%), Miss estimate;the EPS is -1.05 (-5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B278.67%
0.00B70.67%
+0.00B349.34%
EBITMiss expectations
-0.13B18.27%
-0.12B12.70%
-0.01B5.57%
EPSMiss expectations
-1.055.00%
-1.03533.53%
-0.01471.47%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf